Pending final contract, healthcare and pharmaceutical companies GSK and Sanofi announced an agreement with the UK government to supply 60 million doses of the partnership's COVID-19 vaccine, currently under development.
In a news release today, the BNT162b1 COVID-19 vaccine under development by Pfizer and BioNTech displayed early positive results in producing neutralizing antibodies from the partnership's Phase I/II trial.
More than 300 participants have been screened for Imperial's COVID-19 vaccine trial as its lead speaks of "cautious optimism".
British Pharmaceutical company GlaxoSmithKline announced a partnership with Canadian biopharmaceutical company Medicago plans to develop and evaluate a new vaccine against COVID-19.
ZyCoV-D received permission from the Drug Controller General of India - CDSCO for Phase I/II clinical trials to take place in India with human subjects
The inactivated vaccine was granted permission by the Drug Controller General of India, and the Ministry of Health & Family Welfare to begin...
We spoke with Pfizer today and confirmed October remains feasible but is contingent on successful aquisition of an Emergency Use Declaration
Entos Pharmaceuticals (Entos), a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine (Covigenix)